GGSK购买加拿大的35Pharma, 价格95万美元, 以开发HS235, 一种肺高血压实验药物。 GSK to buy Canada’s 35Pharma for $950M to develop HS235, an experimental drug for pulmonary hypertension.

GGSK同意以9.5亿美元购买加拿大的35Pharma药厂,以获得HS235,一种早期研制的与心脏衰竭和肺动脉高血压有关的肺高血压调查药物。 GSK has agreed to acquire Canada’s 35Pharma for $950 million to gain access to HS235, an investigational drug in early development for pulmonary hypertension linked to heart failure and pulmonary arterial hypertension. 该药物已经完成了第一阶段的试验,显示出潜在的代谢和血管效益,并可能比目前的治疗减少出血风险。 The drug, which has completed phase I trials, shows potential metabolic and vascular benefits and may reduce bleeding risks compared to current treatments. 收购支持GSK在1月份收购RAPT治疗药物后扩大其呼吸道和心血管疾病的战略. The acquisition supports GSK’s strategy to expand its pipeline in respiratory and cardiovascular diseases, following its January purchase of RAPT Therapeutics. 这项交易正在等待美国和加拿大的监管批准。 The deal is pending regulatory approval in the U.S. and Canada.